CWA
SGMO

Clarus Wealth Advisors’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Clarus Wealth Advisors’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-1,000
Closed -$11K – 479
2019
Q2 		$11K Hold
1,000
– – 0.01% 428
2019
Q1 		$10K Hold
1,000
– – 0.01% 525
2018
Q4 		$11K Hold
1,000
– – 0.02% 502
2018
Q3 		$17K Hold
1,000
– – 0.01% 466
2018
Q2 		$19K Buy
+1,000
New +$16.6K 0.01% 434

Other funds holding SGMO

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Clarus Wealth Advisors's SGMO Position: Q3 2019 in Review

Clarus Wealth Advisors sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q3 2019, closing a stake of 1,000 shares — an estimated $11K sold.

Clarus Wealth Advisors first reported a position in SGMO in Q2 2018 and held it in 5 quarters. The position peaked at $19K in Q2 2018. 184 funds tracked by Wall St. Rank hold SGMO as of Q3 2019.

  • Clarus Wealth Advisors reported no remaining SANGAMO THERAPEUTICS INC position as of Q3 2019 after selling out during the quarter.
  • Clarus Wealth Advisors sold 1,000 SANGAMO THERAPEUTICS INC shares in Q3 2019, an estimated $11K.
  • Clarus Wealth Advisors first reported a position in SANGAMO THERAPEUTICS INC in Q2 2018 and held it in 5 quarters.
  • Clarus Wealth Advisors's SANGAMO THERAPEUTICS INC position peaked at $19K in Q2 2018.
  • 184 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q3 2019.

Based on Clarus Wealth Advisors's 13F filing for Q3 2019, filed 11 Oct 2019.